Strikingly, EPZ‐6438 (Tazemetostat, TazverikTM), as a first‐in‐class, small molecular inhibitor of EZH2, received accelerated approval in January 2020 by FDA for the treatment of patients (age ≥ 16 years) diagnosed with locally advanced or metastatic epithelioid sarcoma, which are ineligible for complete surgical resection.35 The gene discussed is EZH2; the disease is epithelioid sarcoma.